Traws Pharma Raises $10M Upfront, Up to $60M for UK Flu Challenge
Traws Pharma raised $10 million upfront in a PIPE at $1.6730 per share plus up to $50 million via milestone-based and three-year warrants, totaling $60 million in proceeds. Funds will finance a UK influenza human challenge trial for tivoxavir marboxil and support MHRA approval, shareholder consent and trial data milestones.
1. PIPE Financing Structure
Traws Pharma entered into a private investment in public equity financing that delivers $10.0 million of gross proceeds at $1.6730 per share on closing. The agreement includes milestone-based Series A and B warrants and a three-year Series C warrant, potentially providing up to $50.0 million in additional proceeds.
2. Use of Proceeds
The upfront funds are earmarked for completion of the UK human challenge trial of tivoxavir marboxil, its once-monthly oral influenza prophylactic candidate. This financing secures capital to advance enrollment and dosing while preserving funding for subsequent development stages.
3. Milestone and Warrant Details
Series A warrants can generate approximately $10.0 million upon MHRA approval to start the challenge trial; Series B warrants can add $10.0 million following shareholder approval and trial data release. Series C warrants, exercisable over three years post-shareholder approval, could deliver another $30.0 million.
4. Closing, Registration and ATM Sales
The PIPE priced at-the-market under Nasdaq rules closed on April 15, 2026, with funding expected April 16. Traws Pharma has agreed to file a resale registration statement for the shares and warrants, and retained Cantor Fitzgerald & Co. as lead placement agent.